Abstract |
In 2008, WHO made the JAK2V617F gene mutation as one of the specific molecular diagnostic markers of BCR/ABL-negative myeloproliferative neoplasms (MPN). In 2013 two research teams demonstrated that whole genome sequencing technology (WGS) was used to detect calreticulin gene mutation in essential thrombocythaemia (ET) and primary myelofibrosis (PMF) patients with JAK2V617F⁻ and MPL⁻ mutations. In this review, the relationship of CALR gene mutation with MPN is briefly summarized.
|
Authors | Lu Dong, Xu-Liang Shen, Wu Wei |
Journal | Zhongguo shi yan xue ye xue za zhi
(Zhongguo Shi Yan Xue Ye Xue Za Zhi)
Vol. 23
Issue 5
Pg. 1532-4
(Oct 2015)
ISSN: 1009-2137 [Print] China |
PMID | 26524072
(Publication Type: Journal Article, Review)
|
Chemical References |
- CALR protein, human
- Calreticulin
- Receptors, Thrombopoietin
- MPL protein, human
- JAK2 protein, human
- Janus Kinase 2
|
Topics |
- Bone Marrow Neoplasms
(genetics)
- Calreticulin
(genetics)
- Humans
- Janus Kinase 2
(genetics)
- Mutation
- Myeloproliferative Disorders
(genetics)
- Receptors, Thrombopoietin
(genetics)
|